Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 5 chart positions in 5 markets.
By chart position
- 🇬🇧GB · Life Sciences#26100K to 300K
- 🇯🇵JP · Life Sciences#14100K to 300K
- 🇰🇷KR · Life Sciences#18100K to 300K
- 🇵🇹PT · Life Sciences#583K to 10K
- 🇹🇼TW · Life Sciences#115500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
152K to 457K🎙 Weekly cadence·14 episodes·Last published 6mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
304K to 913K🇬🇧33%🇯🇵33%🇰🇷33%+2 more - Active Followers
Loyal subscribers who consistently listen
91K to 274K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
Part of the Story: Sherlock Holmes and The Adventure of the Silent Hiss
Dec 15, 2025
25m 26s
Confronting the stigma of lung cancer
Dec 10, 2025
27m 12s
Breast cancer: widely known, but often overlooked
Dec 3, 2025
37m 02s
A fair shot: exploring vaccines access and equity
Nov 20, 2025
26m 32s
Uncovering heart failure
Nov 5, 2025
34m 56s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 12/15/25 |  Part of the Story: Sherlock Holmes and The Adventure of the Silent Hiss✨ | cancernarrative change+4 | Brett Harman | The Adventure of the Silent HissThe Return of Sherlock Holmes | — | cancer diagnosisSherlock Holmes+3 | Pfizer Ltd | 25m 26s | |
| 12/10/25 |  Confronting the stigma of lung cancer✨ | lung cancerstigma+3 | Dr Jesme FoxStefano Podesta | Roy Castle Lung Cancer FoundationPfizer UK | — | lung cancerstigma+3 | — | 27m 12s | |
| 12/3/25 |  Breast cancer: widely known, but often overlooked✨ | breast cancerpatient care+3 | Helen DickensColm Doody | Breast Cancer NowPfizer UK | — | breast cancerpatient care+3 | — | 37m 02s | |
| 11/20/25 |  A fair shot: exploring vaccines access and equity✨ | vaccineshealth equity+3 | Lord BethellHetal Naik | Pfizer | UK | vaccineshealth equity+5 | — | 26m 32s | |
| 11/5/25 |  Uncovering heart failure✨ | heart failuresymptoms+3 | Anna TomlinsonSeema Patel | Cardiomyopathy UKPfizer UK | — | heart failuresymptoms+3 | — | 34m 56s | |
| 10/22/25 |  The hidden challenges of multiple myeloma✨ | multiple myelomahealth challenges+3 | Dr Sophie CastellColm Doody | Myeloma UKPfizer UK | UK | multiple myelomaoncology+3 | — | 31m 02s | |
| 10/8/25 |  Gaining independence with haemophilia✨ | haemophiliaindependence+3 | Kate BurtSeema Patel | The Haemophilia SocietyPfizer UK | — | haemophiliaindependence+5 | — | 35m 17s | |
| 11/19/24 |  The vital role of immunisation for disease prevention✨ | immunisationdisease prevention+3 | Sir Jonathan Van-Tam OBEDr Gillian Ellsbury | Pfizer | England | immunisationvaccination+5 | — | 33m 46s | |
| 8/23/24 |  What sickle cell disease tells us about health inequalities✨ | health inequalitiessickle cell disease+3 | John James OBESeema Patel | Sickle Cell SocietyPfizer UK | — | sickle cell diseasehealth inequalities+3 | — | 34m 15s | |
| 4/12/24 |  Understanding the impact of migraine✨ | migrainehealth impact+3 | Rob MusicGillian Ellsbury | The Migraine TrustPfizer UK | — | migrainehealth+6 | — | 34m 54s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 11/22/23 |  Innovation in cancer: Defining the future of care | Dr Ellie Cannon is joined by Jane Lyons, CEO of Cancer52 and Stefano Podesta, Oncology Lead at Pfizer UK, to discuss the big challenges and opportunities in the fight against cancer within the UK. PP-UNP-GBR-13462 / October 2025 | — | ||||||
| 9/13/23 |  Delivering a step forward for rare disease patients | Dr Ellie Cannon is joined by Dr Jacqueline Barry, Chief Clinical Officer at the Cell and Gene Therapy Catapult and Owen Marks, Rare Disease Lead at Pfizer UK (at time of recording), to discuss the urgent need to evolve the way rare disease medicines are brought to patients, and why healthcare systems need to keep pace with scientific advancements. PP-UNP-GBR-12704 / July 2025 | — | ||||||
| 5/10/23 |  Meeting the challenge of Antimicrobial Resistance (AMR) | Dr Ellie Cannon is joined by economist Lord Jim O’Neill (who in 2014 was commissioned to chair a review into the rising increase in drug-resistant infections) and Toby Cousens, Hospital and Internal Medicines Lead at Pfizer UK (at time of recording), to discuss the threat of antimicrobial resistance (AMR) and the challenges it poses both to science and wider society. PP-UNP-GBR-11741 / March 2025 | — | ||||||
| 12/10/22 |  What can we learn from COVID-19 to address other healthcare challenges? | Join Dr Ellie Cannon as she talks to Susan Rienow, Country President at Pfizer UK (at time of recording) and Dr Richard Torbett, CEO of the Association of the British Pharmaceutical Industry, about the lessons learnt from the COVID-19 pandemic and how this could be applied to address other major healthcare challenges. PP-UNP-GBR-10858 / November 2024 | — | ||||||
Showing 14 of 14
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
7 placements across 5 markets.
Chart Positions
7 placements across 5 markets.